bluuebunny/crossref_metadata_2025_split huggingface dataset:
The importance of red cell distribution width on gastric cancer.
Authors: Erdem Dilek , Erdem Emre , Turgut Kurt Yasemin , Topcu Turkan , Kacan Turgut , Gunaldi Meral , Yilmaz Bahiddin 
Published: September 2018

e15502 Background: Red cell distribution width (RDW) is an elevated marker in several cancers like breast, colon, prostate and pancreatic cancer at the time of diagnosis. Gastric cancer (GC) is the fifth most common cancer and also third leading cause of cancer deaths.We aimed to determine whether RDW values differ between gastric cancer and healthy subjects, as well as to evaluate association between RDW and other factors. Also, we examined other two important inflammatory markers in GC patients: neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) Methods: This retrospective study included 68 gastric cancer patients and 42 age and sex matched healthy controls. The exclusion criteria involved cardiac disease, chronic obstructive lung disease, thromboembolism, chronic renal failure, hepatic disorders, hypertension, acute and chronic infections, stroke, hematologic disease and other accompanying cancer. Blood samples were retrospectively obtained from computerized patient database. Results: Among 110 subjects; RDW, NLR and PLR were significantly higher in GC patients when compared to healthy subjects (RDW: 44,9 vs 41,4 p < 0.0001, NLR: 3,40 vs 1,90 p < 0.0001, PLR: 245,9 vs 131,1 p = 0.007). There was no statistically significant association between these markers (RDW, NLR and PLR) and stage, histopathological subgroups and metastasis stage at the time of diagnosis. Conclusions: Elevated RDW is a simple, cheap and readily available marker and may be useful in gastric cancer at the time of diagnosis. Also, NLR and PLR can accompany RDW in the assessment of gastric cancer. Key words: gastric, red cell distribution width, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, cancer
A metabolomic signature for predicting chemosensitivity in gastric cancer.
Authors: García Verdejo Francisco José , Ortega Granados Ana Laura , Díaz Navarro Caridad , Luque Caro Natalia , Fernández Garay David , Álamo de la Gala Maria Carmen , Ruiz Sanjuan María , de la Torre Cabrera Capilla , Fernández Navarro Mónica , Dueñas García Rosario , Navarro Pérez Victor , Martínez Ortega Esther , Cárdenas Quesada Nuria , Jaén Morago Ana , Plata Fernández Yessica , Vicente Pérez Francisca , Genilloud Olga , Lozano Barriuso Ana María , Sanchez Rovira Pedro , Pérez del Palacio Jose 
Published: September 2018

e15504 Background: Perioperative chemotherapy (QT) with platinum and fluoropyrimidines with or without anthracyclines is recommended option in patients with resectable gastric cancer (GC) at least cT2 or nodal involvement. Another option is surgery followed by QT with radiotherapy (QT/RT) or QT without RT in patients with D2 lymphadenectomy. Unfortunately, a considerable percentage of patients progress during neoadjuvant-QT (neo-QT) and some cases become inoperable cancer. These patients could benefit from curative surgery after diagnosis without neo-QT. Currently, histological/molecular markers have not been established to predict which patients can benefit from neo-QT. As potent analysis method, study of blood metabolites of resectable GC patients to establish a profile to differentiate responder patients (R-P) or not-responder (NR-P) to neoadjuvant-QT is promising. To establish a metabolomic profile or metabolomic signature and correlate with chemosensitivity, defined as pathological and clinical response is our endpoint. Methods: To this end we performend an untargeted metabolomic analysis by LC-HRMS of serum samples from resectable GC patients before neo-QT (n = 20 vs n = 10 healthy controls). Chemosensitive tumors were defined as those with good pathological response (Mandard 1 or 2) and partial response by TAC and chemoresistance tumors, defined as those with poor pathological response (Mandard 5) or/and progression by TAC. Reverse phase and HILIC chromatographic modes were applied to deal with highly polar as well as hydrophobic as required for untargeted metabolomics. For identification of potential biomarkers, we used in combination 2 independent variable selection techniques: principal component analysis and Student t test. Results: 11 patients were R-P and 9 patients were NR-P. We observed differences in metabolic profile between patients with GC & healthy controls and R-P & NR-P to neo-QT. Seven identified metabolites contributed most to the differentiating between R-P and NR-P. Conclusions: There are different metabolomic phenotypes among patients R-P and NR-P to neo-QT. It is necessary to validate a metabolomic signature to allow effective chemosensitivity prediction in patients with resectable GC.
Antibody-nanoparticle conjugate constructed with trastuzumab and nab-paclitaxel for the targeted therapy of positive human epidermal growth factor receptor 2 gastric cancer.
Authors: Xiong Jian , Zhang Haijun 
Published: September 2018

e15506 Background: Gastric cancer is the most lethal malignancies in the digestive system. This study was to investigate antibody-nanoparticle conjugate (ANC) constructed with Herceptin® and Abraxane® (Herceptin®/Abraxane®) as a novel strategy of targeted therapy for human epidermal growth factor receptor 2 (HER2) positive gastric cancer. Methods: Firstly, we fabricated the ANC with Herceptin and Abraxane by a “one-step” synthesis using EDC/NHS. In vitro study, the cell viability, apoptosis and cell cycle of the positive HER2 gastric cancer NCI-N87 cells were measured and compared in four groups of PBS, paclitaxel (Taxol), nano- paclitaxel (Abraxane) and ANC (Herceptin/ Abraxane). In addition, we constructed gastric cancer xenograft model in nude mice to evaluate the targeted antitumor effect in vivo. Furthermore, we chose the NIR797 to locate on the ANC and use the NIR imaging to demonstrate that the ANC could more precise target and delayed release of paclitaxel. Results: ANC of Herceptin/Abraxane was spherical in shape and in a suitable size (289.18 nm±102.6 nm). In vitro, the half-maximal inhibitory concentration (IC50), defined as the concentration of Taxol equivalent needed to kill 50% of cells, was found to be 0.24, 0.13 and 0.048 μg/ml for Taxol , Abraxane and ANC of Herceptin/Abraxane respectively for NCI-N87 cells with an excellent dose-effect relationship. Compared with Taxol and Abraxane, ANC of Herceptin/Abraxane could induce significant G2/M arrest. In vivo, at 4 weeks after treatment, mice treated by ANC of Herceptin/Abraxane had a mean tumor volume of 233±24 mm3, Abraxane of 559±97 mm3, Taxol of 871±94 mm3 and PBS as control of 1576±190 mm3. Obviously, the ANC could surpasses Abraxane and Taxol in reducing tumor volume with lesser side effects. Furthermore, NIRF imaging indicated a better targeting and sustained release of paclitaxel with ANC than that with Abraxane and Taxol. Conclusions: Antibody-nanoparticle conjugate of Herceptin/Abraxane could mediate targeted therapy and enhance antitumor activity, which could represent a novel targeted therapeutic agent for positive HER2 gastric cancer.
Multimodality treatment for esophageal cancer in Turkey: A single center experience.
Authors: Demirci Umut , Bugdayci Basal Fatma , Aslan Ferit , Erdur Erkan , Demirci Ayse , Ozatli Tahsin , Oksuzoglu Berna 
Published: September 2018

e15507 Background: Esophagus cancer is an important cause of cancer-related deaths in Turkey as well as in the world. In our study, clinicopathological features and survival results of patients treated for esophageal cancer were presented. Methods: This study retrospectively reviewed esophageal squamous cell carcinoma (SCC) and adenocarcinoma (ADC) patients who were admitted to our center, between 2012 and 2016. Results: A total of 82 patients (56 males) with a median age of 56 years were evaluated. Seventy-one (87%) patients were diagnosed with SCC, 10 (12%) with ADC, 1 with adenosquamous carcinoma. All ADC patients were HER2 negative. The localization of tumors; lower third (55%), middle third (27%) and upper third (18%) of the esophagus. Prior to surgery, neoadjuvant chemoradiotherapy (CRT) was administered in 21 patients (26%); 10 of them receiving carboplatin and paclitaxel (CP), and 11 receiving cisplatin and 5-FU (CF). TNM classification of operated patients were as follows; Stage 1 (n = 5), stage 2 (n = 10), stage 3 (n = 8) and stage 4 (n = 1). Adjuvant chemotherapy (CF) was administered in the other 6 (7%) patients. Definitive CRT was given in 36 patients (44%), with CF being administered in 32 patients, and CP therapy in 4 patients. There were 19 patients (23%) with metastatic diagnosis and 13 of whom were treated with CF, and 4 with docetaxel-cisplatin-5FU combination. With median follow up of 21 months, median overall survival (OS) and time to progression (TTP) were 24 and 17 months, respectively. The median OS and TTP of patients with metastatic disease were 14 and th 9 months, respectively. The median OS and TTP of the patients who underwent surgery were 45 and 34 months, respectively. Conclusions: Our findings in this study regarding the rate of histology, the percentages of patients with metastatic vs. locally advanced disease, and survival rates were similar to the literature.
Diffusion-weighted magnetic resonance imaging for predicting pathologic response to neoadjuvant chemoradiotherapy in esophageal squamous cell cancer.
Authors: Hao Daxuan , Yang Yuanyuan , Li Xue , Wu Xiaoyuan , Chen Yongshun , Wang Jianhua 
Published: September 2018

e15510 Background: Neoadjuvant chemoradiotherapy(nCRT) followed by surgery has became the standard treatment for patients with locally advanced esophageal cancer. However, cumulating data showed that only patients who had a pathologic response to neoadjuvant treatment could benefit from the nCRT and surgery. Moreover, for patients with no pathologic response, nCRT even worsen the survival compared with surgery alone. Therefore, accurately differentiating the two groups was contributed to personalize treatment for esophageal cancer. Our study aimed to explore the potential value of diffusion-weighted magnetic resonance imaging (DWI-MRI) for the prediction of pathologic response to nCRT in esophageal squamous cell carcinoma. Methods: Nineteen patients underwent DWI-MRI within one week before and after nCRT. Tumor regression score (TRG) was assessed by two experienced pathologists after esophagetcomy. The average tumor apparent diffusion coefficient (ADC) of tumor was calculated before and after neoadjuvant treatment. The predictive potential of pre-nCRT ADC (ADCpre), post-nCRT ADC (ADCpost) and ADC change (ΔADC) for pathologic responders (TRG≥3) and good responders (pCR and near-pCR, TRG1-2) was assessed. Results: Among these patients, 12 patients showed a positive response, and 8 patients showed a good response to nCRT. The ADCpre values in responders were significantly higher than these in no-responders (2.31±0.53×10-3mm2/s vs. 1.72±0.40 mm2/s, P= 0.021). According to ROC analysis for ADCpre, an optimal cut-off value of 1.77×10-3mm2/s predicted the responders with a sensitivity of 83.33 %, specificity of 71.43 %, PPV of 83.33 %, NPV of 71.43 %. The ADCpost values in good responders were significantly higher than these in poor responders (3.44±0.62×10-3 mm2/s vs. 2.73±0.31 mm2/s, P= 0.004). The ADCpost was predictive of the good responders at a threshold of 3.21×10-3mm2/s (sensitivity of 87.50 %, specificity of 100.00 %, PPV of 100.00 %, NPV of 91.67 % ). Conclusions: ADC value can be used as a promising biomarker to predict pathologic response of esophageal squamous cell carcinoma to neoadjuvant chemoradiotherapy.
How to reduce splenic injury in laparoscopic radical gastrectomy: Criminal ligament priority separating.
Authors: Wang Wei , Xiong Wenjun , Wan Jin 
Published: September 2018

e15528 Background: Iatrogenic splenic injury may lead to conversion or nontherapeutic splenectomy in laparoscopic gastrectomy. A critical point at splenic injury occurs is improper traction of spleen-omentum ligament which was called crimimal ligament (CL). We aimed to explore the efficacy of cirminal ligament priority separating (CLPS) to reduce iatrogenic splenic injury in laparoscopic radical gastrectomy. Methods: Complete videos of 540 laparoscopic radical gastrectomy in Guangdong Provincial Hospital of Chinese Medicine were reviewed. The relationship between CLPS and iatrogenic splenic injury was determined. CL was defined as the ligament between omentum and spleen. CLPS was defined as that CL was firstly separated when mobilization was in left upper quadrant. Results: CL was present in 81.5% (440/540) and were included for analysis. There was variation in the distribution pattern of CL and it mostly appeared in the lower pole of spleen (414/440). CLPS was performed in 24.5% (108/440) and 75.5% (332/440) were not (un-CLPS). In systematic review, the incidence of iatrogenic splenic injury was 10.9% (48/440). Among these patients, 79.1% (38/48) were due to improper traction of CL and they were all in un-CLPS group. Instrument injury was occurred in 2.2% (10/440) and 3 were in CLPS group and 7 were in un-CLPS group. Most iatrogenic splenic injury were successfully handled with electrocoagulation, adhesive and compression technique, except 2 patients underwent conversion to open splenectomy for serious splenic injury in un-CLPS group. Conclusions: In laparoscopic surgery for gastric cancer, iatrogenic splenic injury mostly resulted from improper traction of CL and CLPS could reduce the incidence of iatrogenic splenic injury.
Significance of Prognostic Nutritional Index in post-surgical outcomes after surgical management in gastric cancer patients.
Authors: Herrera Marytere , Sobrevilla-Moreno Nora , LYRA-GONZALEZ IVAN , Calderillo German , Diaz Consuelo , Ruiz Garcia Erika 
Published: September 2018

e15535 Background: Preoperative nutritional status in gastric cancer patients is not only correlated with postoperative complications, also, prognostic nutritional index or Onodera´s nutritional index (PNI) may relate with overall survival (OS) after gastrectomy. There is no available data of preoperative nutritional status in Mexican population. We decide to explore these variables and analyze its impact in outcomes reported in our population. Methods: This is a retrospective included a total of 91 patients patients with locally advanced gastric cancer confirmed by laparoscopy treated in the National Cancer Institute in México between January 2010 and June 2016. The PNI level was determined according the following formula: 10 x serum albumin (g/dl) + 0.005 x total lymphocyte count (per mm3). The optimal cutoff value of PNI in our population was set at 38.7 according the median, we stratified patients in high (PNI > 38.7) or low (PNI < 38.7) nutritional status, clinicopathologic features were compared. Results: We analyzed 91 patients, the mean patients age was 58, 61.5% were man, the 51.6% went to total gastrectomy with D2 dissection, 56% were pathologic stage III and 61.5% of the patients received adjuvant chemotherapy. The patients with high nutritional status had a OS of 46 months vs patients with low nutritional status with 25 months (p = 0.009). Patients with body mass index (BMI) > 23 had a OS of 41 months vs patients with BMI < 23 with 19 months of OS (p = 0.001), finally the patients with albumin > 3.75 had a 39 months of OS vs 23 months with albumin < 3.75 (p = 0.011) Conclusions: The low PNI group had worse OS than the high PNI group (46 months vs 25 months, p = 0.009). Preoperative is a simple and useful marker to predict overall survival in patients with locally advanced gastric cancer
Presence of bone metastases(BM) at diagnosis is associated with poor prognosis and coagulation disorders (CD) in patients (pts) with advanced gastric cancer (AGC).
Authors: Toppo Laura , Liguigli Wanda , Senti Chiara , Tomasello Gianluca , Ghidini Michele , Ratti Margherita , Botticelli Andrea , Onesti Concetta Elisa , DI Pietro Francesca , Pizzo Claudio , Panni Stefano , Curti Alessandra , Passalacqua Rodolfo 
Published: September 2018

e15538 Background: The presence of BM in AGC is a relatively uncommon finding and has a poor prognosis [Leporini C. 2015]. At diagnosis the presence of BM occurs in approximately 10-15% of pts with AGC.[Park 2011; Silvestris 2013]. Aim of this study is to describe the main features of pts with AGC and BM at diagnosis and the prognostic implications. Methods: A consecutive series of AGC followed at Cremona Oncology Division from November 2004 to Dicember 2016 and included in three consecutive prospective trials [Dalla Chiesa M. 2011; Tomasello G. 2013], were analyzed. All pts were treated with a modified DCF (docetaxel, cisplatin, fluorouracil) given as a dose-dense regimen, every 14 days. We analyzed pts with BM at diagnosis (BMaD) and pts without BMaD. We evaluated baseline clinical and pathological parameters, the presence of coagulation disorders (CD) together with efficacy measures in the two groups. Results:218 pts with AGC were identified (38 with BMaD and 180 without BMaD).Main pts characteristics and results are reported in the Table below. Conclusions: The presence of BM at diagnosis in pts with AGC is not a rare event (21%) and identifies a population with a significantly poorer outcome and a higher incidence of CD, that need a clinical monitoring of coagulation parameters. More efforts are required to understand the reasons of the different prognosis and to find specific treatments to improve the survival. [Table: see text]
IMRT-induced acute hepatic toxicity and analysis of the dose-volume effects in gastric cancer patients treated with postoperative radiation.
Authors: Jing Yu , Zhou Fuxiang , Wen-juan Yang , Jing Dai , Ling Xia , Wen-bo Wang 
Published: September 2018

e15542 Background: To investigate the postoperative-IMRT-induced hepatic toxicity in gastric cancer, and analyze the correlations between liver dose-volumetric parameters and acute hepatic toxicity, so as to give a dose-limitation suggestion for postoperative-IMRT in gastric cancer patients. Methods: Between June 2013 and June 2016, 67 patients with gastric cancer treated with post-operative adjuvant IMRT were reviewed. Prescribed dose was from 45Gy to 54Gy, in a daily fraction of 1.8–2.0 Gy. Dose constraints included: liver V30 < 40%, liver V40 < 30%, a mean dose of two kidneys < 18Gy and one kidney V6 < 50% if a mean dose of another kidney is more than 18Gy or another kidney has been resected. The following clinical and dose-volumetric parameters were examined: age, gender, concurrent chemotherapy, chemotherapy cycles before IMRT, chemotherapy cycles after IMRT, total chemotherapy cycles, Dmean (mean dose to liver), V5, V10, V15, V20, V25, V30, V35, and V40. Acute hepatic toxicity was evaluated between 1 and 4 months after radiation, according to the Common Terminology Criteria for Adverse Events(CTCAE), version 3.0. Results: 46 patients developed grade 1 hepatic toxicity, and 8 patients developed grade 2 hepatic toxicity after radiation, while there was no grade 3 or more severe hepatic toxicity. On univariate analysis, chemotherapy cycles after radiation, total chemotherapy cycles, Dmean, V20, V25, V30, V35 and V40 show correlations with Grade 2 acute hepatic toxicity (p = 0.009, 0.004, 0.015, 0.040, 0.005, 0.001, 0.001, 0.001, respectively). On multivariate analyses, V40 was the only significant parameter correlated with the risk of Grade 2 acute hepatic toxicity (P = 0.002). Using ROC curves, we find that to avoid grade 2 acute hepatic injury, the dose-volumetric limitations would be: Dmean of 22.4Gy, V20 of 42.3%, V25 of 38%, V30 of 27%, V35 of 17%, and V40 of 13%. Conclusions: IMRT is safe for gastric cancer treated with postoperative-radiotherapy as to liver. The grade 2 acute hepatic toxicity could be avoided by restricting dose-volumetric parameters of liver.
Polymorphisms in the PRTOR gene in relation to gastric adenocarcinoma susceptibility in an Eastern Chinese population.
Authors: Wang Meng-Yun , Jia Ming , He Jing , Wei Qing-Yi 
Published: September 2018

e15552 Background: RPTOR is an essential scaffold for MTOR complex which is necessary for the MTOR-catalyzed phosphorylation. Methods: In this study of 1,100 gastric cancer (GCa) cases and 1,137 matched cancer-free controls, we investigated associations between eight potentially functional single nucleotide polymorphisms (SNPs) (rs3751934 C > A, rs1062935 T > C, rs12602885 G > A, rs1468032 T > A, rs1468033 A > G, rs2271610 C > G, rs2271612 C > T, and rs2878052 G > A) in RPTOR and gastric cancer risk in an Eastern Chinese Population. Results: In logistic regression analysis, a significantly increased GCa risk was associated with the rs1468032 AA variant genotype (adjusted odds ratio [OR] = 1.32, 95% confidence interval [CI] = 1.09-1.60) under a dominant model, which remained significant after correction by the false-positive reporting probability. This risk was more evident in subgroups of younger subjects, females, never smokers, never drinkers, cancers of non-cardia and stage of Ⅲ+Ⅳ. We then performed SNP-mRNA expression correlation analysis in GTEx database as well as using real-time PCR in adjacent noncancerous tissues. We found that the AA variant genotype was associated with non-significantly decreased expression of RPTOR mRNA level. Conclusions: Our results suggest that the RPTOR rs1468032 A variant may be markers for GCa susceptibility. Larger, independent studies are warranted to validate our findings.
Effect of Spag5 on proliferation and sensitivity to DNA-damaging chemotherapy.
Authors: Liao Wangjun , Yuan Lezhong , Luo Yuhao , Ma Huanrong 
Published: September 2018

e15556 Background: Chemotherapy based on DNA-damaging anti-cancer drugs remains the most predominant treatment for advanced gastric cancer. The predictors for their sensitivity are under development. Our data showed that sperm-associated antigen 5 (Spag5) contributed to cancer cell proliferation and decreased DNA-damaging drug sensitivity in vivo and vitro. Methods: Spag5 mRNA expression were compared in The Cancer Genome Atlas (TCGA) and GEO datasets (GSE56807, GSE63089, GSE65801), while protein level were detected in 52 patients diagnosed with gastric cancer in Nanfang Hospital by immunohistochemistry. BGC-823 and MGC-803 were transfected with spag5 and control siRNA and then subjected to MTT and EDU assay to verify proliferation rate. Cell viability and apoptosis were tested in spag5-silenced BGC-823 and MGC-803 treated with oxaliplatin, epirubicin and 5-fluorouracil independently. DNA-damaged were detected by comet assay and yH2ax level with western blot. Treatment of oxaliplatin was given intraperitoneally to nude mice carrying xerographs of Shspag5 or control BGC-823 cells every three days. Results: Spag5 mRNA level was significantly upregulated in cancer tissues compared with paired normal tissues in all of the datasets. Immunohistochemistry shows higher protein level of spag5 in paired cancer tissue. Knockdown of Spag5 BGC-823 and MGC-803 showed a significantly decreased proliferation in both MTT and EDU assay. Spag5 silencing led to increase vulnerability to oxaliplatin, epirubicin and 5-fluorouracil, thus less cell viability and more apoptosis. Spag5 knockdown BGC-823 and MGC-803 subjected to DNA-damaging drugs showed upregulated yH2ax level and increased DNA damage in comet assay. Tumor growth rate were significantly reduced in shspag5 group and treatment of oxaliplatin led to relatively higher inhibition of tumor growth. Conclusions: Spag5 serves as a candidate to predict proliferation and chemosensitivity to DNA-damaging chemotherapy.